Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OmniAb (OABI) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for OmniAb (OABI) over the last 5 years, with Q3 2025 value amounting to $28.5 million.

  • OmniAb's Cash & Equivalents rose 477.68% to $28.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.5 million, marking a year-over-year increase of 477.68%. This contributed to the annual value of $27.6 million for FY2024, which is 6871.26% up from last year.
  • OmniAb's Cash & Equivalents amounted to $28.5 million in Q3 2025, which was up 477.68% from $18.3 million recorded in Q2 2025.
  • OmniAb's Cash & Equivalents' 5-year high stood at $33.4 million during Q4 2022, with a 5-year trough of $19847.0 in Q3 2022.
  • For the 5-year period, OmniAb's Cash & Equivalents averaged around $15.8 million, with its median value being $19.1 million (2024).
  • Per our database at Business Quant, OmniAb's Cash & Equivalents plummeted by 9452.05% in 2022 and then skyrocketed by 10694388.57% in 2023.
  • Over the past 5 years, OmniAb's Cash & Equivalents (Quarter) stood at $362203.0 in 2021, then soared by 9118.59% to $33.4 million in 2022, then plummeted by 51.01% to $16.4 million in 2023, then soared by 68.71% to $27.6 million in 2024, then rose by 3.4% to $28.5 million in 2025.
  • Its Cash & Equivalents was $28.5 million in Q3 2025, compared to $18.3 million in Q2 2025 and $10.9 million in Q1 2025.